Several p110δ inhibitors, including idelalisib [162], duvelisib [163], and umbralisib [164], were previously approved by the U.S. Food and Drug Administration for treating various types of leukemia or lymphoma, given the dominant role of p110δ in hematopoietic malignancies. Here, PIK3CD is linked to lymphoma.